Inside the research

Globus Medical, Inc.

GMED Research profile · latest available data

Price overview

$74.52

▲ +0.25 (+0.3%)

52w hi$96.82
52w lo$55.10
Vol1.56M
As of25 Sep 2026

The Verdict

Hold

Our score -0.22

Short-0.39
Medium-0.16
Long-0.03

computed 2026-09-27

Key fundamentals

Globus Medical, Inc.

Healthcare · Medical Devices

Market cap$10.01B
Enterprise value$9.52B
Trailing P/E19.06x
Forward P/E13.80x
EV / EBITDA9.43x
P / S (ttm)3.18x
Profit margin17.0%
Return on equity11.8%
Revenue growth+5.9%
Earnings growth-26.2%
Debt / equity2.35

Layer Breakdown

LayerRawContribution
Fundamental+0.18
Sector+0.08
Technical-0.31
Earnings+0.00
Sentiment+0.05

macro × 1.00 · 2026-09-27

Business overview

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

United States · www.globusmedical.com

Risk Metrics

Beta vs SPX0.95
Corr SPX0.35
Annual vol44.2%
Annual ret+12.0%
Sharpe0.27
Max DD-44.4%

Window: 504 trading days (504 obs)

Analyst Coverage

Mean PT$111.50
High / Low$123.00 / $92.00
Median$115.00
Analysts12
Strong Buy4
Buy6
Hold4
Sell0
Strong Sell0

Recent rating actions

2026-05-08Wells Fargo→ Overweight
2026-05-08RBC Capital→ Outperform
2026-05-08Needham→ Buy
2026-02-26Wells Fargo→ Overweight
2026-02-25Needham→ Buy
2026-02-25Barclays→ Overweight

Material Events

DateEvent8-K
2026-08-06Earnings Release, Exhibitsread
2026-06-04Officer / Director Change, Shareholder Vote…read
2026-05-07Earnings Release, Exhibitsread
2026-03-23Officer / Director Change, Reg FD Disclosure…read
2026-02-24Earnings Release, Exhibitsread
2026-01-07Earnings Release, Exhibitsread
2025-11-06Earnings Release, Exhibitsread
2025-08-07Earnings Release, Exhibitsread
2025-07-21Earnings Release, Officer / Director Change…read
2025-06-05Officer / Director Change, Shareholder Vote…read
2025-05-15Other Material Event, Exhibitsread
2025-05-08Earnings Release, Exhibitsread

SEC Filings

DateFormDoc
2026-08-068-Kview
2026-08-0610-Qview
2026-07-284view
2026-06-094view
2026-06-084view
2026-06-048-Kview
2026-05-0710-Qview
2026-05-078-Kview
2026-04-24DEF 14Aview
2026-04-24DEFA14Aview
2026-03-238-Kview
2026-02-274view
2026-02-248-Kview
2026-02-2410-Kview
2026-02-174view

The Long Run

FY 2012–2025 · 14 years

LineLatestCAGRTrend
Revenue$1.57B+25.6%
Gross profit$759.12M+23.3%
Operating income$479.82M+11.6%
Net income$537.87M+33.0%
Cash from ops$243.50M+9.3%

Indices

S&P MidCap 400

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$74.53$75.10$73.69$74.521.56M
Sep 24$74.21$74.99$73.70$74.271.63M
Sep 23$74.95$75.34$73.75$73.961.46M
Sep 22$74.99$75.73$74.37$75.191.93M
Sep 21$74.00$74.41$73.17$74.291.25M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →